Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells
The pathogenicity of extreme acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been attributed to its skill to enter by means of the membrane-bound angiotensin-converting enzyme 2 (ACE2) receptor. Subsequently, it has been closely speculated that angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) remedy could modulate SARS-CoV-2 an infection.
On this examine, publicity of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) and human endothelial cells (hECs) to SARS-CoV-2 recognized vital variations in protein coding genes concerned in immunity, viral response, and cardiomyocyte/endothelial construction.
Particularly, transcriptome adjustments have been recognized within the tumor necrosis issue (TNF), interferon α/β, and mitogen-activated protein kinase (MAPK) (hPSC-CMs) in addition to nuclear issue kappa-B (NF-κB) (hECs) signaling pathways.
Nevertheless, pre-treatment of hPSC-CMs or hECs with two extensively prescribed antihypertensive drugs, losartan and lisinopril, didn’t have an effect on the susceptibility of both cell kind to SARS-CoV-2 an infection. These findings show the poisonous results of SARS-CoV-2 in hPSC-CMs/hECs and, taken along with newly rising multicenter trials, recommend that antihypertensive drug therapy alone doesn’t alter SARS-CoV-2 an infection.